working

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers


Get Started
Already a member? Log in here

More Content

More Content

TheraCryf (TCF) | FY25 results: expanded portfolio; focus on Ox-1

Companies: TheraCryf PLC

Most popular equity research this week | 2 - 6 Apr

Companies: BNO0RXCMHRE/SCESOGARBBSIXHTONVP/MURAGYEOGCLIGTPTINLGDRTRXSCLPCOSTIMEAVODNLOXBKOOVTETVALYGENABZANSFTCFGTLYPHPAVCTFUTRMCLBURWBIDVLSSY

TheraCryf (TCF) | Pharmaron contracted to progress Ox-1 programme

Companies: TheraCryf PLC

Evgen portfolio update on core field of cancer, 'the R&D is entirely on plan and on budget'

Companies: TheraCryf PLC

TheraCryf (TCF) | £4.3m raise to advance Ox-1 to clinical trial readiness

Companies: TheraCryf PLC

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top